The purpose of the study is to see if a medication called Ravulizumab (ULTOMIRIS) may reduce lung injury in people with pneumonia, acute lung injury (ALI), or acute respiratory distress syndrome (ARDS) that is associated with a COVID 19 infection. ULTOMIRIS is an investigational medication, meaning that it has not been approved by the FDA to treat these conditions. Participants will be randomly assigned (like flipping a coin) to receive the study medication or not receive the study medication. Participants who receive study drug will receive the study drug in their vein up to 4 times in a 2 week period. Study participation will last about 29 days.

The goal of this cohort and biorepository is to collect data and blood specimens on individuals with Nontuberculous Mycobacteria (NTM), pulmonary disease, and healthy adults to better understand the illness and ultimately improve the care and survival of those with these conditions.